Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Resume Discussions on Revising Basic Immunization Plan
March 27, 2023
- Review of Abortion Pill Postponed amid Flock of Public Comments
March 24, 2023
- Xocova to Be Commercially Available from March 31
March 24, 2023
- Additional Safety Measures for Xocova “Not Needed at This Time”: MHLW Panel
March 24, 2023
- MHLW Orders Label Revisions for TB Drugs, Steboronine
March 24, 2023
- Japan to Designate 3 More Diseases as Intractable Illnesses
March 24, 2023
- MHLW Panel Begins Discussions on Revision of Basic Policy for Blood Products
March 23, 2023
- Generic Dispensing Tops 82%; 57% of Pharmacies Not Active on Biosimilars: Poll
March 23, 2023
- Chuikyo’s SaMD Working Group to Compile Opinion by July
March 23, 2023
- Majority of Pharmacists Think Setting Up Integrated Drug Supply Website Is Vital: MHLW Study
March 22, 2023
- Japan to Tap Patient-Initiated Mixed Care Scheme for Pediatric Cancer Meds
March 22, 2023
- MHLW Council Discusses Root Causes of Drug Supply Disruptions, Yakkasa Issues
March 22, 2023
- MHLW Panel OKs 184 More Health Damage Claims for COVID-19 Jabs
March 22, 2023
- Japan Approves J-TEC’s Cell Sheet for Vitiligo, Aurion’s Bullous Keratopathy Therapy
March 22, 2023
- Oral Abortion Pill Mefeego Up for Another Round of Panel Reviews on March 24
March 20, 2023
- Expert Panel Discusses 2% Buffer Zone, Member Floats “Regional Index”
March 20, 2023
- Expert Panel Seeks Revision of Drug Pricing Rules to Stabilize Supplies
March 20, 2023
- Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
March 20, 2023
- 97 Health Damages Reported for Kymriah in Japan: April-September
March 17, 2023
- Japan to Add Purchased Doses of Paxlovid, Xocova to Govt Stockpile
March 17, 2023
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…